Reset filter
Trefwoorden
Demographers ×
Meer tonen Trefwoorden
Inhoudsopgave
  1. 1. Klinische studie
  2. 2. Routinedocumentatie
  3. 3. Register-/kohortstudies
  4. 4. Kwaliteitswaarborging
  5. 5. Datastandaard
  6. 6. Patiëntenvragenlijst
  7. 7. Medisch vakgebied
Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

44 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Prostate Cancer RTOG NCT00023829 - Demographic Data Form Prostate Cancer RTOG NCT00023829

- 22-03-15 - 1 Formulier, 4 Itemgroepen, 40 Data-elementen, 1 Taal
Itemgroepen: Header, Patient characteristics, Family history, Cancer prevention trial
A5 Radiation Therapy Oncology Group Demographic Data Form - Version 2 Adjuvant Radiation Therapy Plus Hormone Therapy Compared With Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer NCT00023829 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=A46CB05D-071D-28BA-E034-080020C9C0E0

DEMOGRAPHICS Roche H0650g Breast Cancer - DEMOGRAPHICS

- 15-03-21 - 1 Formulier, 1 Itemgroep, 8 Data-elementen, 1 Taal
Itemgroep: DEMOGRAPHICS
Study part: Demographics. A phase III multinational, randomized, single-blind study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2/neu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer. "Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche"

Lung Cancer Smoking Survey NCT00324805 - Follow Up Smoking Survey Lung Cancer NCT00324805 ECOG-E1505

- 25-03-15 - 1 Formulier, 3 Itemgroepen, 21 Data-elementen, 1 Taal
Itemgroepen: Header, Smoking status, Nic Alert Test Result
ECOG-E1505 Follow Up Smoking Survey Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-Small Lung Cancer That Was Removed By Surgery NCT00324805 Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=0745B0C2-1A2A-5046-E044-0003BA3F9857

Demographic A0 HQ Confirmation Prostate Cancer NCT00288080

- 20-09-21 - 1 Formulier, 1 Itemgroep, 29 Data-elementen, 1 Taal
Itemgroep: Patient Information
A0 HQ Confirmation - Radiation Therapy Oncology Group PROSTATE:CONFORMAL RT PLUS ANDROGEN ABLATION Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=53DF7CA6-6269-4FBB-E044-0003BA3F9857

Breast Cancer NCT00881361 Demographic - Demographic Worksheet - 2932449v1.0 - Demographic Worksheet

- 17-09-21 - 1 Formulier, 1 Itemgroep, 10 Data-elementen, 1 Taal
Itemgroep: Patient Demographics
Demographic Worksheet Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=70F88030-783B-64C6-E040-BB89AD432159

XELODA and Lapatinib Advanced or Metastatic Breast Cancer Demography NCT00078572

- 20-09-21 - 1 Formulier, 2 Itemgroepen, 8 Data-elementen, 1 Taal
Itemgroepen: Demography, Demography for Females
XELODA and Lapatinib Advanced or Metastatic Breast Cancer Study ID: 100151 Clinical Study ID: EGF100151 Study Title: A Phase III, Randomized, Open-label, Multicenter Study Comparing GW572016 and Capecitabine (XELODA) versus Capecitabine in Women with Refractory Advanced or Metastatic Breast Cancer Clinicaltrials.gov Identifier: NCT00078572 https://clinicaltrials.gov/ct2/show/NCT00078572 Procedure: Demography Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: lapatinib Trade Name: Tyverb,Tykerb,Tycerb Study Indication: Breast Cancer; Neoplasms, Breast

Esophageal Cancer NCT00655876 Demographic - A0 HQ Confirmation - 2904861v1.0 - A0 HQ Confirmation

- 17-09-21 - 1 Formulier, 1 Itemgroep, 29 Data-elementen, 1 Taal
Itemgroep: Patient Information
A0 HQ Confirmation - PHASE III ESOPHAGEAL: RT/PACLITAXEL/CISPLATIN +/ Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=6D4170C3-6E1D-4980-E040-BB89AD435BA5

Breast Cancer NCT00684983 Demographic - NCCTG N0733 Demography Form - 2842806v1.0 - Demography Form NCCTG N0733

- 17-09-21 - 1 Formulier, 5 Itemgroepen, 18 Data-elementen, 1 Taal
Itemgroepen: Patient Identifier, Demographics, Race, Payment, Optional Questions
NCCTG N0733 Demography Form Capecitabine and Lapatinib With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB, Stage IIIC, or Stage IV Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=643B1D4E-2802-CA4C-E040-BB89AD432C8F

Breast Cancer NCT01349322 Demographic - A0 OPEN Form - 1005 - 3198937v1.0 - A0 OPEN Form - 1005

- 09-01-15 - 1 Formulier, 3 Itemgroepen, 27 Data-elementen, 1 Taal
Itemgroepen: Patient Information, Eligibility Checklist, Eligibility Checklist 2
A0 OPEN Form - 1005 Higher-Dose Radiation Therapy or Standard Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=9DA9F360-A112-1EA4-E040-BB89AD432FA2

Anal Cancer NCT00324415 Demographic - AMC-045 Demographic Form (DEM) - 2937136v1.0 - Demographic Form AMC-045

- 24-03-14 - 1 Formulier, 1 Itemgroep, 7 Data-elementen, 1 Taal
Itemgroep: Demographics
AMC-045 Demographic Form (DEM) Cisplatin, Fluorouracil, Cetuximab, and Radiation Therapy in Treating Patients With HIV and Stage I, Stage II, or Stage III Anal Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=72857762-35A6-7AF0-E040-BB89AD434241

Intravenous Topotecan and Gemcitabine as Second-line Treatment in Patients With Ovarian Cancer NCT00061308 - Screening - Demography; Vital Signs

- 16-08-19 - 1 Formulier, 3 Itemgroepen, 16 Data-elementen, 1 Taal
Itemgroepen: Administrative, Demography, Vital Signs
Study ID: 104864/627 Clinical Study ID: 104864/627 Study Title: An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00061308 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan, Gemcitabine Study Indication: Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer

Colorectal Cancer NCT00077233 Demographic - CALGB: 80203 BACKGROUND INFORMATION FORM - 2171121v3.0 - CALGB: 80203 BACKGROUND INFORMATION FORM

- 09-01-15 - 1 Formulier, 1 Itemgroep, 14 Data-elementen, 1 Taal
Itemgroep: CCRR MODULE
CALGB: 80203 BACKGROUND INFORMATION FORM Fluorouracil and Leucovorin Plus Either Irinotecan or Oxaliplatin With or Without Cetuximab in Treating Patients With Previously Untreated Metastatic Adenocarcinoma of the Colon or Rectum Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=BFD5AAD1-D500-39A2-E034-0003BA12F5E7

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial